Daniel Haimowitz, MD
Geriatric Medicine · Levittown, PANPI 1013064377
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.4%), education and travel and lodging — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Acadia Pharmaceuticals Inc at 47.0% of the total. Reporting peaked in 2019 at $7,395 and has fallen 83.8% since, to $1,198 in 2025. Among geriatric medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 93 payments — averaging $166.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acadia Pharmaceuticals Inc$7K
- Intuitive Surgical$3K
- Merck$2K
- Sanofi-aventis U.S. LLC$947
- Pfizer$931
- E.r. Squibb & Sons, L.L.C.$750
- plus $1K from 23 others
What the payments were for
- Consulting fees$7,18146%
- Speaking & faculty fees$1,3729%
- Grants$7505%
- Travel & lodging$2,01213%
- Food & beverage$1,66411%
- Education$2,50016%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acadia Pharmaceuticals Inc | 11 | $7,268 |
| Intuitive Surgical | 2 | $2,517 |
| Merck | 1 | $1,740 |
| Sanofi-aventis U.S. LLC | 3 | $947 |
| Pfizer | 4 | $931 |
| E.r. Squibb & Sons, L.L.C. | 1 | $750 |
| Otsuka America Pharmaceutical, Inc. | 14 | $258 |
| Avanir Pharmaceuticals, Inc. | 7 | $125 |
| Sunovion Pharmaceuticals Inc. | 5 | $120 |
| Lundbeck LLC | 6 | $116 |
| AstraZeneca | 5 | $97 |
| Almatica Pharma LLC | 4 | $83 |
| Novartis | 4 | $62 |
| Biogen | 3 | $46 |
| Corium, LLC | 2 | $46 |
| Teva Pharmaceuticals USA, Inc. | 2 | $42 |
| Actelion Pharmaceuticals US, Inc. | 2 | $38 |
| Smith+Nephew | 2 | $35 |
| Lilly USA, LLC | 2 | $33 |
| Neurocrine Biosciences, Inc. | 2 | $32 |
| AbbVie | 1 | $31 |
| Philips North America LLC | 2 | $29 |
| Bausch Health US, LLC | 2 | $27 |
| Genentech USA, Inc. | 1 | $22 |
| Eisai Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Neurelis, Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $15 |
| Cook Medical LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUPLAZID$7,190
- Da Vinci Surgical System$2,500
How this compares
$15,479 in reported general payments places this provider in the 95th percentile of 217 geriatric medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 381 | $223,342 |
| NuplazidPimavanserin Tartrate | 13 | $67,396 |
| XareltoRivaroxaban | 106 | $66,786 |
| MyrbetriqMirabegron | 81 | $40,701 |
| DescovyEmtricitabine/Tenofov Alafenam | 15 | $31,327 |
| JardianceEmpagliflozin | 42 | $26,959 |
| FarxigaDapagliflozin Propanediol | 45 | $22,020 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $21,467 |
| Rufinamide | 12 | $20,006 |
| JanuviaSitagliptin Phosphate | 20 | $16,779 |
| EntrestoSacubitril/Valsartan | 25 | $16,123 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 29 | $13,965 |
| SantylCollagenase Clostridium Hist. | 34 | $13,357 |
| OzempicSemaglutide | 14 | $13,339 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 17 | $11,909 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $931 | $223,342381 claims |
| Acadia Pharmaceuticals IncNuplazid | $7,268 | $67,39613 claims |
| Johnson & JohnsonXarelto | $19 | $66,786106 claims |
| AstraZenecaFarxiga, Symbicort | $97 | $27,09467 claims |
| MerckJanuvia | $1,740 | $16,77920 claims |
| NovartisEntresto | $62 | $16,12325 claims |
| Smith+NephewSantyl | $35 | $13,35734 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 217 geriatric medicine providers in Pennsylvania.
Other geriatric medicine in Levittown
- Richard StefanacciPhiladelphia$146K
- James LinErie$73K
- Adele TowersPittsburgh$29K
- Michele ZaworaPhiladelphia$21K
- Robert PearlsteinPlymouth Meeting$15K
- Seth CarterErie$14K
- Moushumi KunduHanover$12K
- Jason KarlawishPhiladelphia$11K
- Mario CornacchioneAllentown$11K
- Philip BenyoSugarloaf$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.